Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. - Wikidata - awgldk - TriplyDB

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

http://www.wikidata.org/entity/Q34401962

about

First line vs delayed transplantation in myeloma: Certainties and controversies Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates Anti-angiogenesis therapies: their potential in cancer management Immunomodulatory drugs in multiple myeloma.Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.Thalidomide and dexamethasone: therapy for multiple myeloma.High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Advances in the treatment for haematological malignancies.Treatment of multiple myeloma: an emphasis on new developments.Microarray-based understanding of normal and malignant plasma cells.Bortezomib for multiple myeloma.Proteasome inhibitor bortezomib for the treatment of multiple myeloma.Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.Thalidomide in multiple myeloma: past, present and future.New horizons in multiple myeloma therapy.Current status of new drugs for the treatment of patients with multiple myeloma.Immunotherapy of multiple myeloma: the start of a long and tortuous journey.Maintenance therapy in multiple myeloma.Challenges in multiple myeloma diagnosis and treatment.Melphalan and its role in the management of patients with multiple myeloma.Targeted treatments to improve stem cell outcome: old and new drugs.New therapies in multiple myeloma.An update on drug combinations for treatment of myeloma.Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.

P2860

Q26745957-62C2CF99-C04F-40EF-9649-4AAAAD51CAA9 Q27026478-4FC7FCD0-460F-42CA-90F0-7E2FCA11AB4B Q28077567-0E9C9397-E461-4C50-9C91-AF4F6516C72D Q28539605-BCA7B895-27E4-4E11-ACCE-DFBA38D482AE Q30433139-D51C1F60-2318-47AF-82EF-DD851F5ABD1B Q33376918-F8DF1BBA-93CB-4CE3-BAAD-FF1A813C4296 Q33379044-06FF44A2-8197-4117-A59C-AA41B271AD6A Q33405532-3B583F51-A334-4D75-A181-A31C39789914 Q33424264-D83A6996-8856-47D7-92AF-FEF143C2AF56 Q33639796-423CAA7C-58DC-4095-B244-177410FEC385 Q33956056-8FB25D01-D10B-447F-A6F0-A440D0E4C335 Q34325722-B2A3CA67-C74C-4BCE-83B2-7B64C9915896 Q35588325-7FA1C738-1FBF-4CBE-939D-DD19D64093CD Q35794472-661D0CB9-66D0-4407-A15E-712828712211 Q35802414-DA25561B-0320-43F9-8B79-98A03E2C451D Q35848146-847436DA-5972-4DD9-B5F2-FB88A04B2744 Q35907767-DC8A9547-CF0A-4206-8E37-14FD9CF71094 Q36012111-97C3C206-E115-4857-9565-D8FA95656C10 Q36014687-2824F597-E527-433D-9B4F-FB9D1F795437 Q36284481-E98D1010-D0F7-4EE4-B7F9-C34AE6AB25B9 Q36407446-B447B4CE-B576-4AA5-9EBE-B798CDCF096A Q36429723-A91AB542-C113-4BBE-AB6F-A1E512654AE5 Q36438215-0A39550F-F225-49EB-ABCB-245FD57A4DBB Q36453354-F22A197C-FECB-4EB3-B886-A067B7DBC4FE Q36521862-BA4B1D7D-BBD6-42D4-ACEE-A727D56CF048 Q36523911-6D056390-CB1A-49D4-8A0C-1811FA66848E Q36525841-E22FBF54-2F19-41A8-A5DF-6111124EEDB1 Q36613990-EA98A9D7-AAD8-4639-B196-8E1FE3045D6D Q36616493-217C6A20-F6F2-4EC5-9439-1B07C912C178 Q36636660-6C2E95B7-6E8D-40FD-8A6B-C4E59D833BBB Q36649839-763E87F7-4A1C-470A-8A20-317AE1B4E142 Q36689152-BBFC446E-75FE-4A51-A943-82E79C131A5C Q36754178-3C610659-DDD3-4557-AA67-932E0A570993 Q36852225-6E426DD3-6E81-4858-A41D-33D4F9679738 Q36879132-53ED1DD1-5E53-4793-BB12-5EFDD9B01588 Q36927960-60E79886-F0F5-4B0D-9C81-5604E1460572 Q36986576-F7BEA722-BE52-48BB-85DF-4B18AEA9C469 Q37038973-6551F2EE-ED4B-4B22-8B22-48B58D066389 Q37053190-A8FA89D9-0F2F-4A11-9017-004D1F97FB36 Q37160347-AC3DB30B-F209-4A53-B1A4-84BF623FB865

P2860

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

http://www.wikidata.org/entity/Q34401962

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Superiority of thalidomide and ...... antation for multiple myeloma.

@ast

Superiority of thalidomide and ...... antation for multiple myeloma.

@en

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone

@nl

type

label

Superiority of thalidomide and ...... antation for multiple myeloma.

@ast

Superiority of thalidomide and ...... antation for multiple myeloma.

@en

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone

@nl

prefLabel

Superiority of thalidomide and ...... antation for multiple myeloma.

@ast

Superiority of thalidomide and ...... antation for multiple myeloma.

@en

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone

@nl

P1433

Q34401962-4D2D324A-595B-457A-8C07-5CBFD5F5CBBB

P1476

Q34401962-FA5988DE-551F-4B9A-AF90-A0925711C600

P2093

Q34401962-08B7900F-9C4B-44DE-BA99-6572C8ECD661

Q34401962-0F84F8CD-0AAB-4F40-A4B9-D9D970551F34

Q34401962-0FC398E3-E595-416A-BFCF-F8DED9B008C9

Q34401962-2097CAE1-F7AD-4109-94A4-CDF760F4BDE7

Q34401962-762889CE-8663-4FCA-8764-95E5A9282DD5

Q34401962-87083D68-3DA3-4662-9221-2C20FA03FD38

Q34401962-B006DA93-DFB6-436D-A89F-2C16F1A4BBFF

Q34401962-B04C340A-6E70-40EA-90A7-9D8F13A1A5F5

Q34401962-C591D2BD-1201-4F3E-A6C4-B990D9BE81C8

Q34401962-CD90200F-1E91-4382-B156-42FF448B03B9

P304

Q34401962-B9256881-15F2-4175-86CC-272AAB9F4F4A

P31

Q34401962-1D56C79D-9487-4908-B375-E455E5284C89

P356

Q34401962-C9D49146-9EDE-4FFA-9DFD-660757B343AA

P407

Q34401962-7ACD82B4-6C34-4346-A4D9-E419DC31D6D4

P433

Q34401962-58DB2423-7F10-4856-9522-A60726674912

P478

Q34401962-B9C00DA2-0262-45C7-9E96-210C606FB978

P50

Q34401962-553C77FF-B8B6-4834-AB44-DF63EAB2616D

Q34401962-B6A51EC5-6F39-4166-97A2-37C82FD7DBDE

Q34401962-BC4B6DEF-E83E-4A26-A809-FF9AF8F4F547

Q34401962-FA85AE9D-C5F8-46A9-AAC7-829A934D2AFA

P577

Q34401962-1A2D4626-5404-4107-A721-ECC3F3AEF9E7

P5875

Q34401962-0576F2C4-1BC3-431A-BF9F-D0B5B76E1893

P698

Q34401962-BEE8ED32-7D11-42AE-AE8B-5C57BB1E4503

P921

Q34401962-768E4889-A5B9-4A9D-9A86-72E6BFDE091A

Q34401962-E27A7ACF-76FB-475A-ACA6-7FC58466BF48

P356

BLOOD-2005-02-0522

P1433

P1476

Superiority of thalidomide and ...... antation for multiple myeloma.

@en

P2093

Antonio de Vivo

http://www.w3.org/2001/XMLSchema#string

Bologna 2002 study

http://www.w3.org/2001/XMLSchema#string

Carolina Terragna

http://www.w3.org/2001/XMLSchema#string

Chiara Nicci

http://www.w3.org/2001/XMLSchema#string

Claudia Cellini

http://www.w3.org/2001/XMLSchema#string

Delia Cangini

http://www.w3.org/2001/XMLSchema#string

Elena Zamagni

http://www.w3.org/2001/XMLSchema#string

Michela Ceccolini

http://www.w3.org/2001/XMLSchema#string

Paola Tacchetti

http://www.w3.org/2001/XMLSchema#string

Patrizia Tosi

http://www.w3.org/2001/XMLSchema#string

P304

35-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-02-0522

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Nicoletta Testoni

Michele Baccarani

P577

2005-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7973474

http://www.w3.org/2001/XMLSchema#string

P698

15761019

http://www.w3.org/2001/XMLSchema#string

P921